[Weibo Reports Fourth Quarter and Fiscal Year 2015 Financial Results BEIJING, China, March 2, 2016Weibo Corporation (Weibo or the Company) (NASDAQ: WB), a leading social media in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2015. Fourth Quarter 2015 Highlights · · · · · · · Fiscal Year 2015 Highlights]
[eFuture Announces Unaudited Fourth Quarter and Full Year 2015 Financial Results BEIJING, March 04, 2016 (GLOBE NEWSWIRE) -- eFuture Holding Inc. (Nasdaq:EFUT) (the “Company” or “eFuture”), a leading software and solution provider and a mobile business enabler to China's rapidly growing retail and consumer goods industries, today announced its unaudited financial results for the fourth quarter and full year ended] [Form 6-K 001-33113 eFuture Holding Inc. Room A1103, A1105, A1106-07, Building A, Note: Note: eFuture Holding Inc. David Ren Chief Executive Officer 6-K 1 f6k_030416.htm FORM 6-K]
[SINA Reports Fourth Quarter and Fiscal Year 2015 Financial Results SHANGHAI, ChinaMarch 2, 2016 Fourth Quarter 2015 Highlights · · · Fiscal Year 2015 Highlights · · · We are delighted that SINA closed the year 2015 with a solid quarter on both Weibo and portal. said Charles Chao, Chairman and CEO of SINA. 2015 was a remarkable year for]
[Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued March 2, 2016 (To Prospectus dated June 5, 2015) ,870,000 Shares 3 China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 3,870,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
[SINA Reports Fourth Quarter and Fiscal Year 2015 Financial Results SHANGHAI, ChinaMarch 2, 2016 Fourth Quarter 2015 Highlights · · · Fiscal Year 2015 Highlights · · · We are delighted that SINA closed the year 2015 with a solid quarter on both Weibo and portal. said Charles Chao, Chairman and CEO of SINA. 2015 was a remarkable year for]
[Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued March 2, 2016 (To Prospectus dated June 5, 2015) ,870,000 Shares 3 China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 3,870,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
[BONA FILM GROUP LIMITED ANNOUNCES SHAREHOLDERS VOTE TO APPROVE GOING PRIVATE TRANSACTION Immediately after the completion of the merger, Parent will be beneficially owned by (i) Mr. Dong Yu, the Chairman and Chief Executive Officer of the Company, and his controlled entities, (ii) Uranus Connection Limited, (iii) Alibaba Pictures Group Limited and its affiliated entity, (iv) Willow Investment Limited, an] []
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares Common Stock] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [4 March China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Selling Stockholders Shares Underwriting Agreement We understand that 3,870,000 shares of Common Stock are to be sold by certain stockholders] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – March 1, 2016 The shares to be sold in this offering represent approximately 13.2 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] [China Biologic Announces Pricing of Secondary Offering of Common Stock BEIJING, China – March 2, 2016 China Biologic will not sell any shares of common stock in the offering and will not receive any proceeds from the sale of the Purchased Shares or the Additional Shares. prospectus@morganstanley.com This press release shall not constitute an offer to sell or the solicitation] []
[BONA FILM GROUP LIMITED ANNOUNCES SHAREHOLDERS VOTE TO APPROVE GOING PRIVATE TRANSACTION Immediately after the completion of the merger, Parent will be beneficially owned by (i) Mr. Dong Yu, the Chairman and Chief Executive Officer of the Company, and his controlled entities, (ii) Uranus Connection Limited, (iii) Alibaba Pictures Group Limited and its affiliated entity, (iv) Willow Investment Limited, an] []
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares Common Stock] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [4 March China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Selling Stockholders Shares Underwriting Agreement We understand that 3,870,000 shares of Common Stock are to be sold by certain stockholders] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – March 1, 2016 The shares to be sold in this offering represent approximately 13.2 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] [China Biologic Announces Pricing of Secondary Offering of Common Stock BEIJING, China – March 2, 2016 China Biologic will not sell any shares of common stock in the offering and will not receive any proceeds from the sale of the Purchased Shares or the Additional Shares. prospectus@morganstanley.com This press release shall not constitute an offer to sell or the solicitation] []
